Biomarkers of Kidney Disease

Biomarkers of Kidney Disease
Author: Charles L. Edelstein
Publsiher: Academic Press
Total Pages: 454
Release: 2010-10-27
ISBN 10: 9780123756732
ISBN 13: 0123756731
Language: EN, FR, DE, ES & NL

Biomarkers of Kidney Disease Book Review:

A biomarker is a molecule that is measured as a marker of normal biological processes, disease processes or the response to a diagnostic or therapeutic intervention. Kidney diseases like acute kidney injury, chronic kidney disease, diabetic nephropathy, glomerular disease, renal cancer and preeclampsia still have a high morbidity. Measurement of biomarkers in the blood or urine that detect patients at risk of kidney diseases or that detect kidney diseases in the earliest stage may ultimately result in preventative or earlier or more effective treatments for kidney diseases. Biomarkers of Kidney Disease reviews the basic and clinical research on biomarkers of the common kidney diseases including acute kidney injury, chronic kidney disease, renal cancer, diabetic nephropathy, glomerular disease and preeclampsia. The characteristics of an ideal biomarker of kidney diseases and statistical analysis of biomarker studies is detailed. The latest techniques for biomarker detection like metabolomics and proteomics is covered in the book. This comprehensive book details the latest advances made in the field of biomarker research and development in kidney diseases. The book is an ideal companion for those interested in biomarker research and development, proteomics and metabolomics, kidney diseases, statistical analysis, transplantation and preeclampsia. Presents a comprehensive, translational source for all aspects of renal biomarkers in one reference work Experts in renal disease biomarkers (from all areas of academic and medical research) take readers from the bench research (cellular and molecular mechanism) to new therapeutic approaches

Biomarkers in Kidney Disease

Biomarkers in Kidney Disease
Author: Vinood B. Patel
Publsiher: Unknown
Total Pages: 329
Release: 2021
ISBN 10: 9789400777439
ISBN 13: 9400777434
Language: EN, FR, DE, ES & NL

Biomarkers in Kidney Disease Book Review:

Transfusion Medicine for Pathologists

Transfusion Medicine for Pathologists
Author: Brian Castillo,Amitava Dasgupta,Kimberly Klein,Hlaing Tint,Amer Wahed
Publsiher: Academic Press
Total Pages: 222
Release: 2018-06-29
ISBN 10: 0128143142
ISBN 13: 9780128143148
Language: EN, FR, DE, ES & NL

Transfusion Medicine for Pathologists Book Review:

Transfusion Medicine for Pathologists: A Comprehensive Review for Board Preparation, Certification, and Clinical Practice is a concise study guide designed to complement standard textbooks in the field of clinical pathology. Pathology residents and fellows of transfusion medicine will find this book useful as a preparation tool for their exams. In addition, the book is a valuable timesaver for busy residents looking for a focused and compact study guide on transfusion medicine that will also be ideal for practicing pathologists who cross-cover transfusion medicine in their clinical practice. Incorporates key words at the end of each chapter for quick review before an exam Includes concise and easy-to-digest chapters ranging from Donor Selection and Testing, to Blood Bank Testing, Transfusion Reactions, Apheresis, Hemotherapy, Special Transfusion Situations, and more Focuses on key topics to study for board examinations, saving time during busy residency programs

Kidney Biomarkers

Kidney Biomarkers
Author: Seema S. Ahuja,Brian Castillo
Publsiher: Academic Press
Total Pages: 342
Release: 2020-07-16
ISBN 10: 0128163747
ISBN 13: 9780128163740
Language: EN, FR, DE, ES & NL

Kidney Biomarkers Book Review:

Since laboratory testing and biomarkers are an integral part in the diagnosis and treatment of kidney disease, Kidney Biomarkers: Clinical Aspects and Laboratory Determination covers currently used biomarkers as well as markers that are in development. Laboratories are increasingly more involved in the follow-up confirmatory laboratory testing and this unique volume showcases the collaboration needed to solve diagnostic clinical puzzles between the laboratory and clinician. This volume provides guidance on laboratory test selection and results interpretation in patients. Sources of inaccurate results in the measurement of kidney biomarkers are discussed along with possibility of eliminating such interferences. Each chapter is organized with a uniform easy-to-follow format with insightful case examples highlighting the collaboration between clinical laboratorians and clinicians. Categorizes biomarkers into diagnostic markers, disease follow-up markers, and prognostic biomarkers Include case examples to show the collaboration between the clinical laboratorian and clinician Discusses the application of kidney biomarkers in clinical practice along with addressing laboratory aspects of kidney biomarker determination

Biomarker

Biomarker
Author: Ghousia Begum
Publsiher: BoD – Books on Demand
Total Pages: 248
Release: 2018-09-05
ISBN 10: 1789236665
ISBN 13: 9781789236668
Language: EN, FR, DE, ES & NL

Biomarker Book Review:

This book investigates the emerging use of biomarkers as a diagnostic tool for the identification of patients with an abnormal condition or as a tool for staging the extent of disease, as an indicator of disease prognosis. Chapters in Part I focus on biomarkers for cancer, including breast cancer and pancreatic cancer, as well as circulating microRNA profiling in cancer biomarker discovery. Chapters in Part II focus on biomarkers of other diagnoses/diseases, including sepsis, childhood renal diseases, pulmonary diseases, Alzheimer's, leishmaniasis, and heart failure. This book investigates the emerging use of biomarkers as a diagnostic tool for the identification of patients with an abnormal condition or as a tool for staging the extent of disease, as an indicator of diseases prognosis. The book is of considerable importance for a broad range of people including researchers, clinicians, and university students.

Advances in Nephropathy

Advances in Nephropathy
Author: Thomas Rath
Publsiher: BoD – Books on Demand
Total Pages: 214
Release: 2018-10-24
ISBN 10: 1789842352
ISBN 13: 9781789842357
Language: EN, FR, DE, ES & NL

Advances in Nephropathy Book Review:

Chronic kidney disease (CKD) is a world-wide known disease affecting up to 4% of the population with increasing figures in developing countries. Life expectancy of patients affected by CKD is shortened compared to the overall population and only a minority of patients reach end stage renal disease (ESRD) with the need for dialysis or renal transplantation; death overtakes dialysis. In nine chapters, this book focuses on different aspects related to the pathophysiology and clinical aspects of CKD, providing interesting insights into new and old biomarkers, allowing us to increase diagnostic and prognostic meaningfulness. In addition, chapters deal with new developments in glomerulopathies, but also aspects of the "tubulocentric" shift will be beneficial for the open-minded reader. Nevertheless, new insights into chronic kidney disease (CKD) and acute kidney injury (AKI) are provided.

Acute Kidney Injury Basic Research and Clinical Practice

Acute Kidney Injury   Basic Research and Clinical Practice
Author: X. Ding,M.H. Rosner,C. Ronco
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 166
Release: 2018-01-23
ISBN 10: 3318063118
ISBN 13: 9783318063110
Language: EN, FR, DE, ES & NL

Acute Kidney Injury Basic Research and Clinical Practice Book Review:

Acute Kidney Injury (AKI) is a complex syndrome that is prevalent among hospitalized patients. In recent years, occurrence of AKI events has risen due to a growing susceptibility of fragile and elderly subjects and an increase in the use of complex procedures such as cardiovascular surgery and imaging techniques. Exposure to potentially nephrotoxic drugs, such as new chemotherapeutic agents, is also proving to be a cause of AKI. This book summarizes recent advances in various settings. A reappraisal of current definitions and staging classifications for AKI in the literature is followed by a description of new criteria for identifying patients at risk and characterizing early kidney damage by using biomarkers. Other important topics include the sequelae of AKI and AKI in special populations such as children, the elderly, and those with cancer. The effects of AKI and its consequences on healthcare expenditures are also addressed from several perspectives. AKI management requires the cooperation of different specialists to optimize outcomes. This book is thus a perfect tool not only for nephrologists, but for every specialist involved in the complicated endeavor of improving patient care.

Biomarkers of Kidney Disease

Biomarkers of Kidney Disease
Author: Charles L. Edelstein
Publsiher: Academic Press
Total Pages: 632
Release: 2016-11-08
ISBN 10: 0128030356
ISBN 13: 9780128030356
Language: EN, FR, DE, ES & NL

Biomarkers of Kidney Disease Book Review:

Biomarkers of Kidney Disease, Second Edition, focuses on the basic and clinical research of biomarkers in common kidney diseases, detailing the characteristics of an ideal biomarker. The latest techniques for biomarker detection, including metabolomics and proteomics are covered in the book. This comprehensive book details the latest advances made in the field of biomarker research and development in kidney diseases. The book is an ideal companion for those interested in biomarker research and development, proteomics and metabolomics, kidney diseases, statistical analysis, transplantation, and preeclampsia. New chapters include biomarkers of cardiovascular disease in patients with CKD, biomarkers of Polycystic Kidney Disease, and biomarkers and the role of nanomedicine. Explores both the practical and conceptual steps performed in the discovery of biomarkers in kidney disease Presents a comprehensive account of newer biomarker discover strategies, such as metabolomics and proteomics, all illustrated by clear examples Offers clear translational presentations by the top basic and clinical researchers in each specific renal disease, including AKI, transplantation, cancer, CKD, PKD, diabetic nephropathy, preeclampsia, and glomerular disease

Acute kidney injury

Acute kidney injury
Author: Sics Editore
Publsiher: SICS Editore
Total Pages: 329
Release: 2014-10-01
ISBN 10: 8869302253
ISBN 13: 9788869302251
Language: EN, FR, DE, ES & NL

Acute kidney injury Book Review:

In acute kidney injury (AKI) the ability of the glomeruli to filtrate deteriorates, which leads to a disturbed acid-base and fluid balance as well as to the accumulation of end products of nitrogen metabolism. Within 24 to 48 hours of the onset of the injury the serum creatinine concentration will rise and urine output fall. AKI should be identified before the creatinine concentration is markedly increased and the estimated glomerular filtration rate (eGFR) falls. A typical patient is an elderly individual with pre-existing renal impairment who, for example, contracts acute diarrhoea or receives nephrotoxic drugs (e.g. NSAIDs, ACE inhibitors), i.e. acute-on-chronic kidney disease. Hypovolaemia is the most common cause of oliguria and can be reversed with fluid therapy. The urine output of a seriously ill patient must be monitored. Urinary retention must be identified and treated. The concomitant administration of an ACE inhibitor, diuretic and NSAID increases the risk of AKI.

Biomarkers in Drug Development

Biomarkers in Drug Development
Author: Michael R. Bleavins,Claudio Carini,Mallé Jurima-Romet,Ramin Rahbari
Publsiher: John Wiley & Sons
Total Pages: 784
Release: 2011-09-20
ISBN 10: 1118210425
ISBN 13: 9781118210420
Language: EN, FR, DE, ES & NL

Biomarkers in Drug Development Book Review:

Discover how biomarkers can boost the success rate of drugdevelopment efforts As pharmaceutical companies struggle to improve the success rateand cost-effectiveness of the drug development process, biomarkershave emerged as a valuable tool. This book synthesizes and reviewsthe latest efforts to identify, develop, and integrate biomarkersas a key strategy in translational medicine and the drugdevelopment process. Filled with case studies, the bookdemonstrates how biomarkers can improve drug development timelines,lower costs, facilitate better compound selection, reducelate-stage attrition, and open the door to personalizedmedicine. Biomarkers in Drug Development is divided into eightparts: Part One offers an overview of biomarkers and their role in drugdevelopment. Part Two highlights important technologies to help researchersidentify new biomarkers. Part Three examines the characterization and validation processfor both drugs and diagnostics, and provides practical advice onappropriate statistical methods to ensure that biomarkers fulfilltheir intended purpose. Parts Four through Six examine the application of biomarkers indiscovery, preclinical safety assessment, clinical trials, andtranslational medicine. Part Seven focuses on lessons learned and the practical aspectsof implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including dataintegration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or moreleading experts, including scientists from biotechnology andpharmaceutical firms, academia, and the U.S. Food and DrugAdministration. Their contributions offer pharmaceutical andclinical researchers the most up-to-date understanding of thestrategies used for and applications of biomarkers in drugdevelopment.

Urine Proteomics in Kidney Disease Biomarker Discovery

Urine Proteomics in Kidney Disease Biomarker Discovery
Author: Youhe Gao
Publsiher: Springer
Total Pages: 203
Release: 2014-10-29
ISBN 10: 9401795231
ISBN 13: 9789401795234
Language: EN, FR, DE, ES & NL

Urine Proteomics in Kidney Disease Biomarker Discovery Book Review:

This book systematically summarizes the ideas and technologies used in urine proteome analysis. It argues that change is the core of biomarker definition since the body uses its homeostatic mechanisms to correct changes in the blood. This means that urine is probably a better source of biomarkers than blood. A roadmap to the urinary biomarker era is proposed, and researchers are reminded of the potential opportunities and risks in their study design. Kidney diseases are emphasized as they produce the most significant changes in urine. This book tries to show researchers and graduate students, who are in or entering the field, "all things considered" rather than "the current affair".

Drug Discovery Toxicology

Drug Discovery Toxicology
Author: Yvonne Will,J. Eric McDuffie,Andrew J. Olaharski,Brandon D. Jeffy
Publsiher: John Wiley & Sons
Total Pages: 584
Release: 2016-04-18
ISBN 10: 1119053331
ISBN 13: 9781119053330
Language: EN, FR, DE, ES & NL

Drug Discovery Toxicology Book Review:

As a guide for pharmaceutical professionals to the issues and practices of drug discovery toxicology, this book integrates and reviews the strategy and application of tools and methods at each step of the drug discovery process. • Guides researchers as to what drug safety experiments are both practical and useful • Covers a variety of key topics – safety lead optimization, in vitro-in vivo translation, organ toxicology, ADME, animal models, biomarkers, and –omics tools • Describes what experiments are possible and useful and offers a view into the future, indicating key areas to watch for new predictive methods • Features contributions from firsthand industry experience, giving readers insight into the strategy and execution of predictive toxicology practices

Biomarkers in Renal Disease

Biomarkers in Renal Disease
Author: Mitchell H. Rosner
Publsiher: Nova Publishers
Total Pages: 151
Release: 2008
ISBN 10: 9781604561135
ISBN 13: 1604561130
Language: EN, FR, DE, ES & NL

Biomarkers in Renal Disease Book Review:

Advances in long-term improvement and outcomes of patients with kidney disease will require the use of novel biomarkers to identify patients at high risk for kidney disease and to diagnose kidney disease early for effective treatment. A biomarker is a substance found in the blood, body fluids or tissues that provides a measure of normal biological or pathological processes or response to pharmacological compounds or drugs. There are a wide variety of biomarkers including but not limited to mRNA, proteins and peptides, and lipid molecules. In AKI, important pathophysiological processes such as inflammation, apoptotic and necrotic cell death and, tubule regeneration may be reflected in blood or urine. An array of candidate markers along with clinical information in long-term clinical studies with appropriate analytical methodologies will likely provide prognostic information. Despite well-known limitations, currently the most widely used biomarkers for the early diagnosis of CKD and AKI are proteinuria, serum creatinine and blood urea nitrogen. Most clinicians are aware that serum creatinine and blood urea nitrogen are poor biomarkers due to inherent characteristics of these molecules and handling by the kidney. Creatinine is secreted and urea nitrogen is reabsorbed by the renal tubules. Many endogenous substances interfere in the assay for creatinine. Serum creatinine and urea appear late after acute kidney injury and the serum levels in part depend on the generation (large or small body mass). Acute kidney injury is a non steady state condition thus serum creatinine and urea nitrogen will lag behind kidney injury. For these reasons new biomarkers are imperative. With knowledge of these limitations in use of current biomarkers and the lack of progress in reducing the mortality and morbidity from kidney disease, there has been a great surge of interest in identifying novel biomarkers with a particular emphasis on the early diagnosis of kidney disease. A variety of methods have been employed including transcriptomics, proteomics, gene arrays and lipidomics. Currently, candidate biomarkers have been found in different disorders and have been tested in humans and many candidate biomarkers have yet to be identified. Most studies to date are preliminary and require validation in large multicentre studies followed by commercial assay development validation and testing. This new book outlines the rapid advances made in the field of biomarker development for kidney disease in which a variety of novel molecules have been identified and studied in humans.

Biomarkers

Biomarkers
Author: Vishal S. Vaidya,Joseph V. Bonventre
Publsiher: John Wiley & Sons
Total Pages: 632
Release: 2010-10-05
ISBN 10: 0470452242
ISBN 13: 9780470452240
Language: EN, FR, DE, ES & NL

Biomarkers Book Review:

This book provides an introduction to the field of biomarkers, how they have been and can be used, and how different approaches can be used to identify, characterize, and monitor biomarkers. The book has chapters on topics including HIV, Cancer, Parkinson’s, vascular injury, environmental exposure. A following section discusses the technologies (diagnostics and assays) to detect biomarkers and authors have emphasized the preclinical and clinical manifestation of the injury/disease process.

The Path from Biomarker Discovery to Regulatory Qualification

The Path from Biomarker Discovery to Regulatory Qualification
Author: Federico Goodsaid,William B. Mattes
Publsiher: Academic Press
Total Pages: 206
Release: 2013-07-16
ISBN 10: 0123944082
ISBN 13: 9780123944085
Language: EN, FR, DE, ES & NL

The Path from Biomarker Discovery to Regulatory Qualification Book Review:

The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book—it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. For complimentary access to chapter 13, 'Classic' Biomarkers of Liver Injury, by John R. Senior, Associate Director for Science, Food and Drug Administration, Silver Spring, Maryland, USA, please visit the following site: http://tinyurl.com/ClassicBiomarkers Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities.

Biomarkers in Toxicology

Biomarkers in Toxicology
Author: Ramesh C. Gupta
Publsiher: Academic Press
Total Pages: 1246
Release: 2019-02-13
ISBN 10: 0128146567
ISBN 13: 9780128146569
Language: EN, FR, DE, ES & NL

Biomarkers in Toxicology Book Review:

Biomarkers in Toxicology, Second Edition, is a timely and comprehensive reference dedicated to all aspects of biomarkers that relate to chemical exposure and their effects on biological systems. This revised and completely updated edition includes both vertebrate and non-vertebrate species models for toxicological testing and the development of biomarkers. Divided into several key sections, this reference volume contains new chapters devoted to topics in microplastics, neuroimmunotoxicity and nutraceuticals, along with a look at the latest cutting-edge technologies used to detect biomarkers. Each chapter contains several references to current literature and important resources for further reading. Given this comprehensive treatment, this book is an essential reference for anyone interested in biomarkers across the scientific and biomedical fields. Evaluates the expansive literature, providing one resource covering all aspects of toxicology biomarkers Includes completely revised chapters, along with additional chapters on the newest developments in the field Identifies and discusses the most sensitive, accurate, unique and validated biomarkers used as indicators of exposure Covers special topics and applications of biomarkers, including chapters on molecular toxicology biomarkers, biomarker analysis for nanotoxicology, development of biomarkers for drug efficacy evaluation, and much more

Accelerating the Development of Biomarkers for Drug Safety

Accelerating the Development of Biomarkers for Drug Safety
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation
Publsiher: National Academies Press
Total Pages: 100
Release: 2009-08-20
ISBN 10: 0309131243
ISBN 13: 9780309131247
Language: EN, FR, DE, ES & NL

Accelerating the Development of Biomarkers for Drug Safety Book Review:

Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.

Renal Fibrosis Mechanisms and Therapies

Renal Fibrosis  Mechanisms and Therapies
Author: Bi-Cheng Liu,Hui-Yao Lan,Lin-Li Lv
Publsiher: Springer
Total Pages: 709
Release: 2019-08-09
ISBN 10: 9811388717
ISBN 13: 9789811388712
Language: EN, FR, DE, ES & NL

Renal Fibrosis Mechanisms and Therapies Book Review:

This book systemically presents the latest research on renal fibrosis, covering all the major topics in the field, including the possible mechanisms, biomarkers, and strategies for prevention and treatment of chronic kidney disease (CKD). Due to its high prevalence, CKD represents a huge global economic and social burden. Irrespective of the initial causes, CKD progresses to end stage kidney disease (ESKD) due to renal fibrosis, which is characterized by glomerulosclerosis, tubule atrophy and atresia, and the excessive accumulation of extracellular matrix (ECM) in the kidney. Unfortunately, an estimated 1%-2% of the adult population living with CKD will need renal replacement therapy at some point as a result of ESKD. As such, strategies for preventing or slowing CKD progression to ESKD are of utmost importance, and studies aiming to understand the mechanisms of renal fibrosis have been the focus of intensive research. Recently, novel insights into the pathophysiological processes have furthered our understanding of the pathogenesis of renal fibrosis, and more importantly, promoted studies on the early diagnosis and treatment of CKD. This book draws lessons from the extensive, state-of-the-art research in this field, elaborating the new theories and new techniques to offer readers a detailed and comprehensive understanding of renal fibrosis and as well as inspiration for future research directions.

ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes

ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes
Author: J.A. Kellum,P.A. McCullough,R.L. Mehta,P.T. Murray,C. Ronco
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 216
Release: 2013-05-14
ISBN 10: 3318024074
ISBN 13: 9783318024074
Language: EN, FR, DE, ES & NL

ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes Book Review:

Associated with both acute kidney injury (AKI) and cardio-renal syndromes (CRS), new biomarkers represent both a popular area of investigation and a new opportunity for advancement of therapy. This book contains the resolutions of the most recent ADQI conferences on biomarkers in AKI (Dublin) and on cardio-renal syndromes (Venice). The first part answers specific questions about new biomarkers and their use and utility in AKI: What are the most suitable candidate molecules and physiologic measures, how solid and evidence based is the discovery phase? How can we incorporate the new biomarkers in the AKI conceptual model describing the evolution from susceptibility to insult, decreased GFR and organ death? Even if we have a positive biomarker pattern and we can identify patients at risk or patients with early or even subclinical AKI, how is this information affecting our clinical behavior and practice? The second part is dedicated to the appraisal of the current knowledge about the pathophysiological mechanisms involved in different forms of CRS: it contains contributions on the state-of-the-art knowledge and practice of CRS, particularly focusing on the pathophysiology of the five subtypes. Acute and chronic mechanisms of damage are explored in depth, with particular attention to the primacy of organ involvement and the subsequent pathways of organ crosstalk.Presenting the most recent research in the field of biomarkers, AKI and CRS, this publication is an important educational tool for advanced investigators and clinical experts, but also for students and fellows.

Chronic Kidney Disease Dialysis and Transplantation

Chronic Kidney Disease  Dialysis  and Transplantation
Author: Jonathan Himmelfarb,Mohamed H. Sayegh
Publsiher: Saunders
Total Pages: 737
Release: 2010
ISBN 10: 9781437709872
ISBN 13: 1437709877
Language: EN, FR, DE, ES & NL

Chronic Kidney Disease Dialysis and Transplantation Book Review:

A companion to Brenner and Rector's The Kidney-covers all clinical management issues relevant to chronic kidney disease. Drs. Jonathan Himmelfarb and Mohamed Sayegh lead a team of expert contributors to present you with the latest advances in hypertensive kidney disease, vitamin D deficiency, diabetes management, transplantation, and more. Himmelfarb and Sayegh give you all of the basic science and clinical tools to properly manage patients with chronic renal disease.